Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort studyReportar como inadecuado




Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Health Services Research

, 14:429

Utilization, expenditure, economics and financing systems

Abstract

BackgroundTreatment-emergent comorbid events TECs are common In patients initiating treatment with pegylated interferon alpha PEG-IFN-alfa and ribavirin for chronic hepatitis C virus HCV infection. The purpose of this study was to estimate the incidence and incremental cost of these events.

MethodsIn a retrospective cohort analysis of healthcare claims, we studied patients with HCV who were newly treated with PEG-IFN-alfa-ribavirin between 2006 and 2008. TECs were defined by new medical-pharmacy claims for predefined conditions in the 12 months after treatment initiation. The net incremental cost of the TECs was the difference between baseline and follow-up costs for these comorbidities and their treatment, excluding PEG-IFN-alfa-ribavirin costs.

ResultsOf 3,795 newly treated patients, 1,269 mean age 50.2, 36.2% female met the selection criteria. New TECs were common, with 61.6% of patients having ≥1 event. Anemia was identified in 29.2% of patients, fatigue in 16.4%, depression in 11.5%, and neutropenia in 11.0%. The mean incremental cost for the predefined TEC in the postindex period was $6,377 $2,782 for medical and $3,595 for pharmacy claims.

ConclusionsIn an insured US cohort with chronic HCV infection, TECs with PEG-IFN-alfa-ribavirin were common and increased costs by approximately $6,000 per treated patient. This estimate may be conservative because it excludes indirect costs. Costs might increase with new regimens that include a protease inhibitor because additional TECs may be expected. Better-tolerated therapies that reduce the financial burden on the healthcare system and improve patient experience are needed.

KeywordsInsurance claims Retrospective study Pegylated interferon alpha Ribavirin Electronic supplementary materialThe online version of this article doi:10.1186-1472-6963-14-429 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Sandhya Sapra - Eunice Chang - Michael S Broder - Gilbert L’Italien

Fuente: https://link.springer.com/







Documentos relacionados